Affordable Access

Access to the full text

Perspectives in immunotherapy: meeting report from the “Immunotherapy Bridge 2018” (28–29 November, 2018, Naples, Italy)

Authors
  • Ascierto, Paolo A.1
  • Bifulco, Carlo2
  • Buonaguro, Luigi3
  • Emens, Leisha A.4
  • Ferris, Robert L.4
  • Fox, Bernard A.5
  • Delgoffe, Greg M.4
  • Galon, Jérôme6
  • Gridelli, Cesare7
  • Merlano, Marco8
  • Nathan, Paul9
  • Odunsi, Kunle10
  • Okada, Hideho11
  • Paulos, Chrystal M.12
  • Pignata, Sandro13
  • Schalper, Kurt A.14
  • Spranger, Stefani15
  • Tortora, Giampaolo16
  • Zarour, Hassane17
  • Butterfield, Lisa H.18
  • And 1 more
  • 1 Unit of Medical Oncology and Innovative Therapy, Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, Via Mariano Semmola, Naples, 80131, Italy , Naples (Italy)
  • 2 Providence Portland Medical Center, Portland, OR, USA , Portland (United States)
  • 3 Cancer Immunoregulation Unit, Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, Naples, Italy , Naples (Italy)
  • 4 University of Pittsburgh, Pittsburgh, PA, USA , Pittsburgh (United States)
  • 5 Laboratory of Molecular and Tumor Immunology, Robert W. Franz Cancer Center in the Earle A. Chiles Research Institute at Providence Cancer Institute, Portland, Oregon, USA , Oregon (United States)
  • 6 National Institute of Health and Medical Research, INSERM, Cordeliers Research Center, Paris, France , Paris (France)
  • 7 Hospital “San Giuseppe Moscati”, Avellino, Italy , Avellino (Italy)
  • 8 Oncology Department, ASO Santa Croce e Carle Cuneo, Cuneo, Italy , Cuneo (Italy)
  • 9 Mount Vernon Cancer Centre, Northwood, Middlesex, UK , Middlesex (United Kingdom)
  • 10 Department of Gynaecologic Oncology, Executive Director, Center for Immunotherapy, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA , Buffalo (United States)
  • 11 University of California San Francisco, Parker Institute for Cancer Immunotherapy, San Francisco, California, USA , California (United States)
  • 12 Medical University of South Carolina (MUSC), Charleston, SC, USA , Charleston (United States)
  • 13 Uro-Gynaecological Department, Istituto Nazionale Tumori Fondazione G. Pascale, IRCCS, Naples, Italy , Naples (Italy)
  • 14 Yale School of Medicine, Translational Immuno-oncology Laboratory, Yale Cancer Center, Medical Oncology, Yale School of Medicine and Yale Cancer Center, New Haven, CT, USA , New Haven (United States)
  • 15 The Koch Institute for Integrative Cancer Research at MIT and Department of Biology, Massachusetts Institute of Technology, Cambridge, MA, USA , Cambridge (United States)
  • 16 Fondazione Policlinico Universitario Gemelli, IRCCS, Rome, Italy , Rome (Italy)
  • 17 University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA , Pittsburgh (United States)
  • 18 Parker Institute for Cancer Immunotherapy Research Center, UCSF, San Francisco, California, USA , California (United States)
  • 19 Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA , New York (United States)
Type
Published Article
Journal
Journal for ImmunoTherapy of Cancer
Publisher
Springer (Biomed Central Ltd.)
Publication Date
Nov 29, 2019
Volume
7
Issue
1
Identifiers
DOI: 10.1186/s40425-019-0798-3
Source
Springer Nature
Keywords
License
Green

Abstract

Immunotherapy is now widely established as a potent and effective treatment option across several types of cancer. However, there is increasing recognition that not all patients respond to immunotherapy, focusing attention on the immune contexture of the tumor microenvironment (TME), drivers of the immune response and mechanisms of tumor resistance to immunity. The development of novel immunotherapeutics and their use in combination with checkpoint inhibitors and other standard of care and novel treatment modalities is an area of particular attention across several tumor types, including melanoma, lung, ovarian, breast, pancreatic, renal, head and neck, brain and non-melanoma skin cancers. The 4th Immunotherapy Bridge meeting (28–29 November, 2018, Naples, Italy) focused on a wide range of evolving topics and trends in the field of cancer immunotherapy and key presentations from this meeting are summarised in this report.

Report this publication

Statistics

Seen <100 times